Cingulate inc stock
Web20 hours ago · KANSAS CITY, Kan., April 14, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed … WebApr 14, 2024 · KANSAS CITY, Kan., April 14, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. …
Cingulate inc stock
Did you know?
WebFeb 24, 2024 · Cingulate ( CING) stock is rising higher on positive ADHD treatment news. The company’s lead candidate, CTx-1301, can apparently be taken with or without food. … WebCingulate currently has two (2) product candidates, CTX-1301 and CTX-1302, that are being developed to serve the approximate $18 billion annual U.S. ADHD market. A third product …
WebDec 10, 2024 · The Company granted the underwriters a 45-day over-allotment option to purchase up to an additional 624,999 shares of common stock and/or warrants to … WebCompany profile page for Cingulate Inc including stock price, company news, press releases, executives, board members, and contact information
WebView CING Stock Real Time Quote, Cingulate Inc stock price with interactive chart, get the latest alerts for Cingulate Inc, with indicator levels, dividend and earnings details. Add a … WebApr 14, 2024 · KANSAS CITY, Kan., April 14, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed …
WebCingulate Inc 52 week high is $2.00 as of April 15, 2024. What is the 52-week low for Cingulate Inc? 52 week low is the lowest price of a stock in the past 52 weeks, or one year.
Web20 hours ago · Cingulate to Participate in Benzinga All Live Access Event. 2024-04-14 14:00 ET - News Release. KANSAS CITY, Kan., April 14, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of … immunology sydneyWebMar 10, 2024 · Inside Cingulate Inc.'s 10-K Annual Report: Financial - Expense Highlight. We have experienced, and will continue to experience, increased expenses associated with being a public company, including costs of accounting, audit, legal, regulatory and tax compliance services; director and officer insurance; and investor and public relations … list of wealthiest americans 2021WebFeb 24, 2024 · Matthew Brams, MD, Cingulate Inc’s Chief Medical Officer, said: “CTx-1301 is being developed to provide the proven efficacy of stimulants while addressing the key challenges associated with available formulations, including sub-optimal onset and duration along with burdensome medication regimens which often lead to non-compliance, … immunology system diseasesWebApr 4, 2024 · In addition to the Phase 3 adult dose-optimization study, Cingulate plans to commence its pivotal Phase 3 fixed-dose pediatric and adolescent study in mid-2024. Assuming positive clinical results from the Phase 3 trials, Cingulate plans to submit a New Drug Application (NDA) for CTx-1301 in the first half of 2024 under the Section 505(b)(2 ... list of wdw attractionsWebHeadquarters. Kansas City. Employees. 15. Founded. 2013. Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery … immunology tacoma waWebCingulate Inc. 1901 West 47th Place. Kansas City, Kansas 66205. Phone 1 913 942-2300. Industry Pharmaceuticals. Sector Health Care/Life Sciences. immunology tcuWebAegis Capital Corp. acted as Lead Bookrunning Manager on a $25 Million Initial Public Offering of Common Stock for Cingulate Inc. (NASDAQ: CING) ACCESSWIRE-5.40%. … immunology templates powerpoint